Biora Therapeutics Inc (BIOR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biora Therapeutics Inc stock (BIOR) is currently trading at $0.22. Biora Therapeutics Inc PE ratio is 0.61. Biora Therapeutics Inc PS ratio (Price-to-Sales) is 0.74. Analyst consensus price target for BIOR is $34.00. WallStSmart rates BIOR as Sell.
- BIOR PE ratio analysis and historical PE chart
- BIOR PS ratio (Price-to-Sales) history and trend
- BIOR intrinsic value — DCF, Graham Number, EPV models
- BIOR stock price prediction 2025 2026 2027 2028 2029 2030
- BIOR fair value vs current price
- BIOR insider transactions and insider buying
- Is BIOR undervalued or overvalued?
- Biora Therapeutics Inc financial analysis — revenue, earnings, cash flow
- BIOR Piotroski F-Score and Altman Z-Score
- BIOR analyst price target and Smart Rating
Biora Therapeutics Inc
📊 No data available
Try selecting a different time range
BIOR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Biora Therapeutics Inc (BIOR)
BIOR trades at a significant discount to its Graham intrinsic value of $2.45, offering a 91% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Biora Therapeutics Inc (BIOR) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap. Significant fundamental concerns warrant caution or avoidance.
Biora Therapeutics Inc (BIOR) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Revenue surging 15800.00% year-over-year
Supporting Valuation Data
Biora Therapeutics Inc (BIOR) Areas to Watch (2)
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 36.00%
Supporting Valuation Data
Biora Therapeutics Inc (BIOR) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 4.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (0.74) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 15800.00%.
The Bear Case
The primary concerns are Market Cap, Institutional Own..
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, growth sustainability, with Revenue Growth at 15800.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Market Cap and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BIOR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BIOR's Price-to-Sales ratio of 0.74x sits near its historical average of 0.74x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is -1% below its historical high of 0.74x set in Feb 2026, and 1% above its historical low of 0.74x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Biora Therapeutics Inc (BIOR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Biora Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 860,000 with 15800% growth year-over-year.
Key Findings
Revenue growing at 15800% YoY, reaching 860,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 652% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Biora Therapeutics Inc maintain 15800%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Biora Therapeutics Inc.
Bottom Line
Biora Therapeutics Inc is a high-conviction growth story with revenue accelerating at 15800% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Biora Therapeutics Inc(BIOR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.